Multiple myeloma is a malignancy of immunoglobulin-secreting plasma cells that is now
often treated in the newly diagnosed and relapsed and/or refractory settings with …

With the gradual improvement of treatment regimens, the survival time of multiple myeloma
(MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an …

Belantamab mafodotin, an immuno‐conjugate targeting B‐cell maturation antigen, showed
single‐agent activity in phase 1 and 2 studies, and was recently approved for heavily …

Simple Summary Patients with multiple myeloma (MM) who become refractory to three or
more lines of therapy (RRMM patients) have few valid therapeutic alternatives. Among them …

Belantamab mafodotin (BLMF) is a B‐cell maturation antigen‐directed antibody‐drug
conjugate, recently approved for advanced multiple myeloma (MM). The impact of BLMF …

Introduction Belantamab mafodotin (BM) is a new anti-BCMA antibody–drug conjugate,
recently approved for triple-class relapsed and refractory multiple myeloma (RRMM). We …

Simple Summary Refractoriness to the five main myeloma treatments, including
lenalidomide, pomalidomide, bortezomib, carfilzomib, and either daratumumab or …

Introduction The pace at which the identification of novel therapeutic targets has led to the
approval of multiple myeloma (MM) agents during the last two decades is nothing more than …

Introduction Immunotherapies targeting B cell maturation antigen (BCMA) in multiple
myeloma are transitioning through trials and entering the clinic, and will likely become a …

Belantamab mafodotin is an antibody drug conjugate directed against B-cell maturation
antigen and was approved by the Food and Drug Administration under accelerated approval …